Dominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now owns 220,937 shares in the company, valued at $9,142,373.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Vericel Stock Up 2.4 %

NASDAQ VCEL opened at $41.66 on Friday. Vericel Co. has a twelve month low of $32.28 and a twelve month high of $54.10. The stock has a market cap of $2.02 billion, a P/E ratio of -4,166.00 and a beta of 1.67. The company’s 50-day simple moving average is $45.26 and its 200 day simple moving average is $46.70.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $52.70 million for the quarter, compared to analyst estimates of $52.59 million. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The company’s revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) EPS. Research analysts anticipate that Vericel Co. will post 0.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Canaccord Genuity Group initiated coverage on Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock. StockNews.com lowered shares of Vericel from a “hold” rating to a “sell” rating in a research report on Tuesday, October 8th. HC Wainwright increased their price target on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, August 2nd. TD Cowen boosted their price objective on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Canaccord Genuity Group started coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 target price for the company. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.71.

Institutional Investors Weigh In On Vericel

A number of hedge funds have recently made changes to their positions in the company. MCF Advisors LLC grew its stake in Vericel by 86.1% during the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after buying an additional 223 shares during the last quarter. CWM LLC grew its position in Vericel by 319.0% during the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 504 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Vericel by 9.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 220 shares in the last quarter. Lazard Asset Management LLC raised its position in Vericel by 178.7% in the 1st quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 1,657 shares during the last quarter. Finally, RiverPark Advisors LLC acquired a new position in Vericel in the first quarter worth $147,000.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.